Petra Bencurova1,2,3, Jiri Baloun1,2,3, Katerina Musilova1,3, Lenka Radova1, Boris Tichy1, Martin Pail2,3, Martin Zeman3,4, Eva Brichtova3,5, Marketa Hermanova3,6, Sarka Pospisilova1, Marek Mraz1, Milan Brazdil1,2,3. 1. Central European Institute of Technology, Masaryk University, Brno, Czech Republic. 2. Department of Neurology, Brno Epilepsy Center, St. Anne's University Hospital, Brno, Czech Republic. 3. Medical Faculty of Masaryk University, Brno, Czech Republic. 4. Department of Forensic Medicine, St. Anne's University Hospital, Brno, Czech Republic. 5. Department of Neurosurgery, St. Anne's University Hospital, Brno, Czech Republic. 6. First Department of Pathological Anatomy, St. Anne's University Hospital, Brno, Czech Republic.
Abstract
OBJECTIVE: Mesial temporal lobe epilepsy (mTLE) is a severe neurological disorder characterized by recurrent seizures. mTLE is frequently accompanied by neurodegeneration in the hippocampus resulting in hippocampal sclerosis (HS), the most common morphological correlate of drug resistance in mTLE patients. Incomplete knowledge of pathological changes in mTLE+HS complicates its therapy. The pathological mechanism underlying mTLE+HS may involve abnormal gene expression regulation, including posttranscriptional networks involving microRNAs (miRNAs). miRNA expression deregulation has been reported in various disorders, including epilepsy. However, the miRNA profile of mTLE+HS is not completely known and needs to be addressed. METHODS: Here, we have focused on hippocampal miRNA profiling in 33 mTLE+HS patients and nine postmortem controls to reveal abnormally expressed miRNAs. In this study, we significantly reduced technology-related bias (the most common source of false positivity in miRNA profiling data) by combining two different miRNA profiling methods, namely next generation sequencing and miRNA-specific quantitative real-time polymerase chain reaction. RESULTS: These methods combined have identified and validated 20 miRNAs with altered expression in the human epileptic hippocampus; 19 miRNAs were up-regulated and one down-regulated in mTLE+HS patients. Nine of these miRNAs have not been previously associated with epilepsy, and 19 aberrantly expressed miRNAs potentially regulate the targets and pathways linked with epilepsy (such as potassium channels, γ-aminobutyric acid, neurotrophin signaling, and axon guidance). SIGNIFICANCE: This study extends current knowledge of miRNA-mediated gene expression regulation in mTLE+HS by identifying miRNAs with altered expression in mTLE+HS, including nine novel abnormally expressed miRNAs and their putative targets. These observations further encourage the potential of microRNA-based biomarkers or therapies. Wiley Periodicals, Inc.
OBJECTIVE:Mesial temporal lobe epilepsy (mTLE) is a severe neurological disorder characterized by recurrent seizures. mTLE is frequently accompanied by neurodegeneration in the hippocampus resulting in hippocampal sclerosis (HS), the most common morphological correlate of drug resistance in mTLE patients. Incomplete knowledge of pathological changes in mTLE+HS complicates its therapy. The pathological mechanism underlying mTLE+HS may involve abnormal gene expression regulation, including posttranscriptional networks involving microRNAs (miRNAs). miRNA expression deregulation has been reported in various disorders, including epilepsy. However, the miRNA profile of mTLE+HS is not completely known and needs to be addressed. METHODS: Here, we have focused on hippocampal miRNA profiling in 33 mTLE+HS patients and nine postmortem controls to reveal abnormally expressed miRNAs. In this study, we significantly reduced technology-related bias (the most common source of false positivity in miRNA profiling data) by combining two different miRNA profiling methods, namely next generation sequencing and miRNA-specific quantitative real-time polymerase chain reaction. RESULTS: These methods combined have identified and validated 20 miRNAs with altered expression in the humanepileptic hippocampus; 19 miRNAs were up-regulated and one down-regulated in mTLE+HS patients. Nine of these miRNAs have not been previously associated with epilepsy, and 19 aberrantly expressed miRNAs potentially regulate the targets and pathways linked with epilepsy (such as potassium channels, γ-aminobutyric acid, neurotrophin signaling, and axon guidance). SIGNIFICANCE: This study extends current knowledge of miRNA-mediated gene expression regulation in mTLE+HS by identifying miRNAs with altered expression in mTLE+HS, including nine novel abnormally expressed miRNAs and their putative targets. These observations further encourage the potential of microRNA-based biomarkers or therapies. Wiley Periodicals, Inc.
Authors: Petra Bencurova; Jiri Baloun; Jakub Hynst; Jan Oppelt; Hana Kubova; Sarka Pospisilova; Milan Brazdil Journal: Sci Rep Date: 2021-05-06 Impact factor: 4.379
Authors: Chelsie M Estey; Curtis W Dewey; Mark Rishniw; David M Lin; Jennifer Bouma; Joseph Sackman; Erica Burkland Journal: Front Vet Sci Date: 2017-11-08
Authors: Morten T Venø; Cristina R Reschke; Gareth Morris; Niamh M C Connolly; Junyi Su; Yan Yan; Tobias Engel; Eva M Jimenez-Mateos; Lea M Harder; Dennis Pultz; Stefan J Haunsberger; Ajay Pal; Janosch P Heller; Aoife Campbell; Elena Langa; Gary P Brennan; Karen Conboy; Amy Richardson; Braxton A Norwood; Lara S Costard; Valentin Neubert; Federico Del Gallo; Beatrice Salvetti; Vamshidhar R Vangoor; Amaya Sanz-Rodriguez; Juha Muilu; Paolo F Fabene; R Jeroen Pasterkamp; Jochen H M Prehn; Stephanie Schorge; Jens S Andersen; Felix Rosenow; Sebastian Bauer; Jørgen Kjems; David C Henshall Journal: Proc Natl Acad Sci U S A Date: 2020-06-24 Impact factor: 11.205
Authors: Kristina D Yakovleva; Diana V Dmitrenko; Iulia S Panina; Anna A Usoltseva; Kirill A Gazenkampf; Olga V Konovalenko; Elena A Kantimirova; Maxim A Novitsky; Regina F Nasyrova; Natalia A Shnayder Journal: Int J Mol Sci Date: 2022-01-16 Impact factor: 5.923